PetVivo Holdings, Inc. announced the addition of Ms. Sherry Grisewood, Mr. Robert Rudelius and Mr. Joe Jasper to the Board of Directors. The addition of these Executives with their individual talents to the Board of Directors displays the continued commitment that PetVivo Holdings, Inc., has toward making this Company a major entity in the Bio-Tech sector. As displayed in the following biographies, all three of these individuals have had numerous years of experience in the business world bordering the Life Sciences and Animal Science arena. Sherry Grisewood is a Chartered Financial Analyst (CFA) who since 2014 has served as a Director, Chair of the Audit Committee and a member of the Compensation Committee of TapImmune, Inc., a NASDAQ-listed public comapny. Ms. Grisewood also is the co-founder and Director of Mobitech Regenerative Medicine, a private medical device company. From December 2012 to June 2017, Ms. Grisewood was associated with Dawson James Securities, Inc., first as Managing Director of Corporate Finance and later as Managing Partner, Life Science Research. From 2010 to the present, Mr. Rudelius has served on the Board of Directors of AxoGen, Inc., the leading company focused specifically on the science, development and commercialization of technologies for peripheral nerve regeneration and repair. Joseph Jasperis a Chartered Financial Analyst (CFA) who since 2005 has been Chief Executive Officer of Vermillion Research, an institutional investment firm, while being responsible for its day-to-day operational management.
PetVivo Holdings, Inc. is a biomedical device company. The Company is focused on the manufacturing, commercialization, and licensing of medical devices and therapeutics for animals. The Companyâs lead product Spryng with OsteoCushion Technology, is a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions, such as osteoarthritis in dogs and horses. The Company is primarily engaged in the business of commercializing and licensing products in the veterinary market to treat and/or manage afflictions of companion animals, such as dogs and horses. Its products are derived from biomaterials that simulate a bodyâs cellular tissue by virtue of their reliance upon natural protein and carbohydrate compositions, which incorporate such tissue building blocks as collagen, elastin, and proteoglycans such as heparin. The Company has a pipeline of therapeutic devices for both veterinary and human clinical applications.
PETVIVO HOLDINGS, INC. 
